China's National Medical Products Administration (NMPA) has approved Hong Kong-based Harbour BioMed's Investigational New Drug (IND) application for HBM4003, the next generation anti-CTLA-4 antibody in combination with PD-1 antibody/chemotherapy intended for the treatment of patients with advanced NSCLC and solid tumours, it was reported on Thursday.
The study is to assess the safety, tolerability, PK/PD, and anti-tumour activity of the product in combination with PD-1 antibody, with or without chemotherapy, in subjects with advanced NSCLC and other solid tumours.
The product is the fully human anti-CTLA-4 monoclonal heavy chain only antibody generated from Harbour Mice. It has already received US FDA and China NMPA IND approvals of the mono therapy and another combination therapy in China. It has completed patient dosing in several patients in its ongoing phase I study in Australia.
EU Commission decides not to renew AstraZeneca and J&J COVID-19 vaccine contracts next year
Publix suspends administration of Johnson & Johnson COVID-19 vaccine based on CDC and FDA guidance
Publix suspends administration of Johnson & Johnson COVID-19 vaccine based on CDC and FDA guidance
SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Frankel Named to Precision BioSciences B oard of Directors
Sobi launches phase 3 trial of efanesoctocog alfa in children with haemophilia A